In this report, Technavio covers the present scenario and growth prospects of the global anticoagulant market for 2017-2021 (base year: 2016). To calculate the market size, the report considers revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

PART 01: Executive summary 6

PART 02: Scope of the report 17

Market overview 17

Top-vendor offerings 18

PART 03: Market research methodology 19

Research methodology 19

Economic indicators 19

PART 04: Introduction 20

Key market highlights 20

PART 05: Disease overview 21

PART 06: Pipeline analysis 23

PART 07: Market landscape 25

Market overview 25

Five forces analysis 27

PART 08: Market segmentation by ROA 28

Oral anticoagulants 29

Injectable anticoagulants 29

PART 09: Market segmentation by drug class 31

Factor Xa inhibitors 32

DTIs 34

Heparin 35

Vitamin K antagonists 36

PART 10: Market segmentation by application 38

DVT 38

PE 38

AF 39

Others 39

PART 11: Geographical segmentation 41

Global anticoagulant market in Americas 41

Anticoagulant market in EMEA 42

Anticoagulant market in APAC 43

PART 12: Market drivers 44

Increasing demand for NOACs 44

Growing prevalence of coagulation disorders 44

Increase in hip and knee surgeries 45

PART 13: Impact of drivers 46

PART 14: Market challenges 47

Increasing cost of NOACs 47

Lack of antidotes in the market for NOACs 47

Patent expiry: a threat to market 47

PART 15: Impact of drivers and challenges 49

PART 16: Market trends 50

Strategic alliance 50

Increasing focus toward emerging economies 50

Patient assistance programs 51

PART 17: Vendor landscape 52

Competitive scenario 52

Other prominent vendors 55

PART 18: Key vendor analysis 56

Bayer HealthCare 56

Boehringer Ingelheim 60

Bristol-Myers Squibb 63

Daiichi Sankyo 68

Johnson & Johnson 71

Sanofi 73

PART 19: Appendix 77

List of abbreviations 77

PART 20: Explore Technavio 78